Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Shares Issued (2016 - 2025)

Altimmune (ALT) has disclosed Shares Issued for 16 consecutive years, with -$72.3 million as the latest value for Q3 2025.

  • Quarterly Shares Issued fell 183.46% to -$72.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $96.9 million through Sep 2025, down 44.14% year-over-year, with the annual reading at $41000.0 for FY2025, 74.53% down from the prior year.
  • Shares Issued for Q3 2025 was -$72.3 million at Altimmune, down from $72.4 million in the prior quarter.
  • The five-year high for Shares Issued was $121.0 million in Q3 2022, with the low at -$72.3 million in Q3 2025.
  • Average Shares Issued over 5 years is $31.6 million, with a median of $24.2 million recorded in 2022.
  • The sharpest move saw Shares Issued tumbled 331.27% in 2021, then skyrocketed 108150.0% in 2024.
  • Over 5 years, Shares Issued stood at -$52.1 million in 2021, then skyrocketed by 332.11% to $121.0 million in 2022, then crashed by 99.93% to $80000.0 in 2023, then soared by 120650.0% to $96.6 million in 2024, then tumbled by 174.82% to -$72.3 million in 2025.
  • According to Business Quant data, Shares Issued over the past three periods came in at -$72.3 million, $72.4 million, and $170000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.